Altanova Pharma Group AG
Swiss specialty pharma platform · Zug, Switzerland

Altanova builds differentiated therapeutic franchises through pharmaceutical-quality execution, regulated market access and integrated medical-channel infrastructure.

About Altanova
Chronic disease focusPatient need and clinical utility guide the portfolio.
Regulated commercializationProduct status, release and market access managed as one system.
Asset-light by designFocused on the regulated commercial layer, with specialist operations performed by qualified partners.
Pharmaceutical qualityQuality, evidence and medical governance built into each product pathway.

For each therapeutic franchise, Altanova manages product strategy, quality, supply, medical affairs and patient access. Appropriately licensed partners carry out manufacturing, testing, logistics and dispensing, as well as cultivation where applicable.

Airlock into a pharmaceutical cleanroom
01

Qualified product inputs

Products and suppliers are assessed against defined quality, regulatory and commercial requirements before entering the platform.

Handover of a sealed pharmaceutical shipment
02

Swiss manufacture and release

Testing, manufacture and technical release are performed through qualified licensed partners under Altanova’s quality architecture.

Physician at a desk in a consulting room
03

Medical-channel access

Specialist pharmacies, wholesalers and compliant medical engagement support controlled Swiss commercialization.

Two people in conversation across a consultation desk
04

Evidence and portfolio learning

Product and treatment data inform portfolio decisions, medical confidence and future market-access strategy.

The evidence loop feeds back into product strategy, quality and access.

Explore our operating model
Built for chronic care

Chronic conditions require ongoing management. Our patient access model brings together physician-led treatment, dispensing through licensed Swiss pharmacies, patient support and structured follow-up.

Together, these elements are designed to support continuity for patients and give treating healthcare professionals relevant information to review treatment over time. Follow-up can also guide future portfolio and access decisions.

Explore patient access
Portfolio

Altanova builds franchises where differentiated therapies, regulated access and disciplined medical-channel execution can address persistent patient needs and create durable pharmaceutical value.

Cannexa
Altanova’s launch therapeutic franchise

Cannexa

Cannexa develops cannabinoid-based medical products for selected chronic disease areas. Its portfolio begins with standardised formulations intended for use under medical supervision and is designed to progress towards differentiated pharmaceutical presentations, supported by consistent quality standards and regulated patient access.

Therapeutic focus

Chronic and neuropathic pain

Pain that persists or recurs for longer than three months and often requires long-term management.

Learn more

Oncology supportive care

Care that addresses symptoms associated with cancer and its treatment, throughout the course of care.

Learn more

Spasticity-related symptoms

Involuntary muscle stiffness and spasms in neurological conditions, managed over many years.

Learn more
Partnerships

Altanova partners where established scientific, technical, manufacturing or commercial capabilities can accelerate execution. The company retains responsibility for the regulated commercial architecture while qualified partners perform specialized activities where ownership does not create differentiated value.

Our partnering approach